Navigation Links
Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Apr 18, 2007 - Gemin X today announced the presentation of positive preclinical data from a study of its lead compound, GX15-070 (obatoclax), in infant acute lymphoblastic leukemia (ALL). The study was discussed in an oral presentation at the Annual Meeting of the American Association for Cancer Research (AACR). According to the study, GX15-070 demonstrated potent single agent activity against ALL blast cells, and also enhanced chemosensitivity and was synergistic with cytotoxic drugs. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.

In this study, researchers obtained leukemia blast cells from five infants and one child with primary ALL. The blasts were exposed to GX15-070 as a single agent in vitro for three days. In all six cases, GX15-070 exhibited potent single agent activity and IC(50) values were within clinically achievable concentrations. High BCL-2 expression and low expression of particular BH3-only BCL-2 family mRNAs in this disease correlate with GX15-070 sensitivity in vitro.

"GX15-070 is an appropriate candidate for ALL treatment because the imbalanced expression of Bcl-2 family proteins in this cancer leads to impaired apoptosis," said Gordon Shore, Ph.D., Chief Scientific Officer of Gemin X. "Additionally, this study further upholds what we already have observed about our lead candidate's utility as a single agent and in combination with other therapies."

These data were presented by Dr. Alena Zhang from Dr. Carolyn Felix's laboratory at Children's Hospital of Philadelphia on April 17 at 3:40 PM in an abstract titled, "BCL-2:BH3-only pro-apoptotic gene expression ratios correlate with in vitro sensitivity of primary MLL(+) infant acute lymphoblastic leukemia to small molecule pan-BCL-2 family inhibitor GX15-070."

Gemin X is currently conducting several clinical trials of GX15-070 in multiple cancer types as a combination therapy and as a single agent. Gemin X recently initiated a Phase 1b trial with GX15-070 in combination with bortezomib in patients with mantle cell lymphoma (MCL) and a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. GX15-070 is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma, myelofibrosis with myeloid metaplasia, myelodysplastic syndrome, and follicular lymphoma both as single agent and in combination with rituximab. In multiple Phase 1 studies, GX15-070 was well-tolerated and resulted in clinical and biological activity.

About Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a fast-growing cancer of the white blood cells, which the body uses to fight infections. The disease is characterized by the bone marrow's overproduction of immature, unformed cells called blasts that would normally develop into mature lymphocytes. These abnormal blasts cannot fight infections, grow quickly, and interfere with normal red blood cells, white blood cells, and platelets. Approximately 4,000 new cases of ALL are diagnosed in the United States each year, and it is fatal if left untreated, because the disease can spread to the bloodstream and organs quickly. It mainly appears in children younger than 10, but one-third of cases are in adults. ALL is the most common form of infant leukemia.

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, GX15-070, is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apopt osis in p53-defective cancers. Gemin X is privately held and is located in Montreal, Quebec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com

Contact

MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
or
Gemin X Biotechnologies Inc.
Diane Viens, 514-281-8989 ext.387
dviens@geminx.com


'"/>




Related medicine technology :

1. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
2. Gemin X Announces Publication of Preclinical Data of GX15-070 in Multiple Myeloma in Blood
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... Clarius Mobile Health, a digital healthcare ... this week at the American Congress of Obstetricians ... San Diego, CA from May ... perfect tool for clinicians to easily confirm pregnancy, ... pregnancy-related complications like ectopic pregnancy and placenta previa," ...
(Date:5/4/2017)... 4, 2017  A new tight-tolerance microextrusion medical ... highly-engineered materials, is being launched by Natvar, a ... developed in recent years to service a wide ... applications. More expensive materials such as glass and ... due to their ability to consistently hold tolerances. ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... The American Parkinson Disease Association’s ... grant submissions all vying for nearly $1,000,000 in funding that will be awarded ... American Parkinson Disease Association (APDA) is focused on advancing scientific research that will ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology Business Management ... on current legislative activity and the latest regulatory concerns impacting RBMA members. The ... 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons Corner ...
(Date:5/26/2017)... ... 26, 2017 , ... Somnoware, a leading provider of digital ... its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device integration ... platform, initializing devices and importing studies are just one-click operations. This plugin streamlines ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are ... menus. , “Boar’s Head fresh sliced meats and cheeses featured in these ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional ... passed the U.S. House on May 4, would result in 23 million Americans losing ... implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , “It ...
Breaking Medicine News(10 mins):